期刊
DRUG DISCOVERY TODAY
卷 21, 期 7, 页码 1181-1188出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.05.012
关键词
-
Estrogen receptor (ER)-positive breast cancer represents the majority (similar to 70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据